Clinical study of norfloxacin in the treatment of acute epididymitis

急性精巣上体炎20例に, NFLXを1回200 mg 1日3回14日間投与し, その臨床効果および安全性につき検討した.1) 7日目で著効9例, 有効10例, 無効1例で有効率95%であった.14日目では著効12例, 有効6例, 無効1例で有効率95%であった.2) 14日目では, 発熱, 疼痛, 腫脹すべて消失したものが8例(7日目では2例)と多く, 7日目に比し効果の増大が認められた.3)投与前膿尿の認められたものは, 20例中13例.尿培養陽性は13例中4例であった.これら膿尿および細菌尿に対しても, 本剤はすぐれた効果を示した.4)末梢血中白血球数, 血沈値, CRPについても本剤投与により, 全般に明らかな改善が認められた.5)自他覚副作用および臨床検査値異常変動は全例で認められなかったThe efficacy and safety of Norfloxacin were studied in the treatment of 20 patients with acute epididymitis. Norfloxacin was orally administered at a dose of 200 mg 3 times a day for 14 days. Clinical efficacy rate on the 7th day was 95% (19/20), excellent in 9 cases, moderate in 10 cases and poor in 1 case, and on the 14th day was 95% (18/19), excellent in 12 cases, moderate in 9 cases and poor in 1 case. On the 14th day, fever, pain and swelling had disappeared in 8 cases (in 2 cases on the 7th day). The efficacy on the 14th day was further investigated compared to that on the 7th day. Before treatment with Norfloxacin, in 13 of the 20 patients, pyuria was observed. Cultivating the bacteria was isolated in 4 of the 13 patients. Norfloxacin remarkably affected the treatment of these patients with pyuria and bacteriuria. In the treatment with Norfloxacin, the count of leukocytes, erythrocyte sedimentation rate and CRP were obviously improved. Side effects and abnormal clinical laboratory findings were not observed. From these results, Norfloxacin 600 mg/day, t.i.d was considered useful and safe in the treatment of acute epididymitis

Concomitant therapy with cefmenoxime and cefsulodin for refractory complicated urinary tract infection (especially caused by Pseudomonas aeruginosa)

CMX, CFSの併用療法を, 難治性で緑膿菌感染が疑われる複雑性尿路感染症を対象に行った.1)効果判定症例91例中総合有効率は73%であった.これらのうち緑膿菌検出例44例では75%, その他の細菌による感染例47例では70%の有効率であった.2)疾患病態群別総合臨床効果はカテーテル留置群を含めいずれの群でも60%以上の有効率を示した.3)細菌学的効果は全体で91%の消失率であり, そのうち緑膿菌82%, セラチア100%, シトロバクター100%, クレブシェラ100%などグラム陰性菌では特に高い消失率を示した.また投与後菌出現率は20%と比較的低率でその多くはYLOであった.4)自他覚的副作用発現頻度は2.4%, 臨床検査値異常化は7.4%にみられたがこれらはいずれも軽度かつ一過性であったCefmenoxime (2 g) and cefsulodin (1 g) were given twice daily for 5 days by concomitant intravenous drip infusion (mixed infusion) to 135 patients with complicated urinary tract infection (c-UTI) probably caused by Pseudomonas aeruginosa. The clinical efficacy was evaluated according to the criteria proposed by the UTI committee in Japan. Ninety one subjects met the criteria for c-UTI and were evaluable for drug efficacy. P. aeruginosa was detected in 44 cases (including mixed infection with other organisms). The overall efficacy rate was 73% of the 91 cases; 75% of the 44 cases with P. aeruginosa and 70% in the 47 cases without P. aeruginosa infection. As to bacteriological response, the eradication rate was 91% (105/116) for all cases. By organism, the eradication rate for P. aeruginosa, Serratia spp. and Citrobacter spp. were 82 (36/44), 100 (12/12) and 100% (10/10), respectively. The eradication rate for gram-negative rods was 93% (99/107). Twenty-three strains appeared after treatment, and the majority of them (13) were yeast-like organisms. There was only one strain of P. aeruginosa. As for side effects, eruption was found in 2 cases. Cefmenoxime and cefsulodin were administered concomitantly to patients with c-UTI which was suspected to be caused by P. aeruginosa. The high overall efficacy rate of about 70% on the average was obtained regardless of the causative organism and disease state. The eradication rate of as high as about 90% was obtained excluding Enterococcus faecalis. Neither severe side effects nor abnormal laboratory values were found. It appeared, therefore, that this dosage regimen was useful for the treatment of refractory complicated urinary tract infection